LETTER
Sarcopenic Obesity: Definition, Health Consequences and Clinical Management
Marwan El Ghoch1, 2, *, Simona Calugi2, Riccardo Dalle Grave2
Article Information
Identifiers and Pagination:
Year: 2018Volume: 12
First Page: 70
Last Page: 73
Publisher Id: TONUTRJ-12-70
DOI: 10.2174/1874288201812010070
Article History:
Received Date: 19/7/2018Revision Received Date: 19/9/2018
Acceptance Date: 22/9/2018
Electronic publication date: 17/10/2018
Collection year: 2018
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Over the last decade, a new condition, which occurs in the presence of both sarcopenia and obesity, has been termed “sarcopenic obesity”. The term describes the coexistence of obesity, defined as the increase in body fat mass deposition, and sarcopenia, defined as the reduction in lean mass and muscle strength. However, many uncertainties still surround the condition of sarcopenic obesity in terms of its definition, the adverse short- and long-term health effects (i.e., medical disease, psychosocial functioning, quality of life and mortality) and its clinical management. The aim of this short communication is to emphasize some crucial aspects that future research should take into account in order to avoid bias and misinterpretations and to underline that the study of sarcopenic obesity should be considered a scientific and clinical priority, as reported by the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO).
